These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32563288)

  • 41. Mind matters: placebo enhances reward learning in Parkinson's disease.
    Schmidt L; Braun EK; Wager TD; Shohamy D
    Nat Neurosci; 2014 Dec; 17(12):1793-7. PubMed ID: 25326691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Selective Role for Dopamine in Learning to Maximize Reward But Not to Minimize Effort: Evidence from Patients with Parkinson's Disease.
    Skvortsova V; Degos B; Welter ML; Vidailhet M; Pessiglione M
    J Neurosci; 2017 Jun; 37(25):6087-6097. PubMed ID: 28539420
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The temporal precision of reward prediction in dopamine neurons.
    Fiorillo CD; Newsome WT; Schultz W
    Nat Neurosci; 2008 Aug; 11(8):966-73. PubMed ID: 18660807
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The anatomy of the mesolimbic reward system: a link between personality and the placebo analgesic response.
    Schweinhardt P; Seminowicz DA; Jaeger E; Duncan GH; Bushnell MC
    J Neurosci; 2009 Apr; 29(15):4882-7. PubMed ID: 19369556
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dopaminergic modulation of the reward system in schizophrenia: a placebo-controlled dopamine depletion fMRI study.
    da Silva Alves F; Bakker G; Schmitz N; Abeling N; Hasler G; van der Meer J; Nederveen A; de Haan L; Linszen D; van Amelsvoort T
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1577-86. PubMed ID: 23978392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The placebo effect in Parkinson's disease.
    de la Fuente-Fernández R; Stoessl AJ
    Trends Neurosci; 2002 Jun; 25(6):302-6. PubMed ID: 12086748
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Triad-conditioning transcranial magnetic stimulation in Parkinson's disease.
    Hanajima R; Terao Y; Shirota Y; Ohminami S; Tsutsumi R; Shimizu T; Tanaka N; Okabe S; Tsuji S; Ugawa Y
    Brain Stimul; 2014; 7(1):74-9. PubMed ID: 24183477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI.
    MacDonald PA; MacDonald AA; Seergobin KN; Tamjeedi R; Ganjavi H; Provost JS; Monchi O
    Brain; 2011 May; 134(Pt 5):1447-63. PubMed ID: 21596772
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine controls Parkinson's tremor by inhibiting the cerebellar thalamus.
    Dirkx MF; den Ouden HE; Aarts E; Timmer MH; Bloem BR; Toni I; Helmich RC
    Brain; 2017 Mar; 140(3):721-734. PubMed ID: 28073788
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release.
    Abosch A; Kapur S; Lang AE; Hussey D; Sime E; Miyasaki J; Houle S; Lozano AM
    Neurosurgery; 2003 Nov; 53(5):1095-102; discussion 1102-5. PubMed ID: 14580276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The placebo response in Parkinson's disease. Parkinson Study Group.
    Shetty N; Friedman JH; Kieburtz K; Marshall FJ; Oakes D
    Clin Neuropharmacol; 1999; 22(4):207-12. PubMed ID: 10442249
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Understanding the mechanisms of placebo and nocebo effects.
    Frisaldi E; Shaibani A; Benedetti F
    Swiss Med Wkly; 2020 Aug; 150():w20340. PubMed ID: 32920787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ketamine Suppresses the Ventral Striatal Response to Reward Anticipation: A Cross-Species Translational Neuroimaging Study.
    Francois J; Grimm O; Schwarz AJ; Schweiger J; Haller L; Risterucci C; Böhringer A; Zang Z; Tost H; Gilmour G; Meyer-Lindenberg A
    Neuropsychopharmacology; 2016 Apr; 41(5):1386-94. PubMed ID: 26388147
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reward Prediction Errors in Drug Addiction and Parkinson's Disease: from Neurophysiology to Neuroimaging.
    García-García I; Zeighami Y; Dagher A
    Curr Neurol Neurosci Rep; 2017 Jun; 17(6):46. PubMed ID: 28417291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GLP-1 receptor agonists for Parkinson's disease.
    Mulvaney CA; Duarte GS; Handley J; Evans DJ; Menon S; Wyse R; Emsley HC
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012990. PubMed ID: 32700772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The placebo response: neurobiological and clinical issues of neurological relevance.
    Pollo A; Benedetti F
    Prog Brain Res; 2009; 175():283-94. PubMed ID: 19660663
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Attenuated neural response to gamble outcomes in drug-naive patients with Parkinson's disease.
    van der Vegt JP; Hulme OJ; Zittel S; Madsen KH; Weiss MM; Buhmann C; Bloem BR; Münchau A; Siebner HR
    Brain; 2013 Apr; 136(Pt 4):1192-203. PubMed ID: 23442226
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Repetitive transcranial magnetic stimulation of the primary motor cortex in the treatment of motor signs in Parkinson's disease: A quantitative review of the literature.
    Zanjani A; Zakzanis KK; Daskalakis ZJ; Chen R
    Mov Disord; 2015 May; 30(6):750-8. PubMed ID: 25786995
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New insights into the placebo and nocebo responses.
    Enck P; Benedetti F; Schedlowski M
    Neuron; 2008 Jul; 59(2):195-206. PubMed ID: 18667148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.